These 2 Elements in Novavax's Earnings Report Could Mean Billions for the Biotech

Novavax (NASDAQ: NVAX) reported a widening loss in the most recent quarter. And, as a clinical-stage biotech, the company doesn't generate product revenue. But I'm not surprised or worried about those facts. I'm more focused on two elements in the earnings report that could mean billions of dollars in revenue for Novavax -- as early as this year.

Of course, both of these points have to do with the company's investigational coronavirus vaccine. Novavax may be next to cross the vaccine-race finish line. The company said it plans to complete an Emergency Use Authorization (EUA) request with the U.S. Food and Drug Administration (FDA) in the second quarter. So, let's take a look at the billion-dollar elements that may transform Novavax.

Image source: Getty Images.

Continue reading

Source Fool.com